123 related articles for article (PubMed ID: 37384621)
1. Polymeric Nanoformulation of Zoledronic Acid Rescues Osteoblasts from the Harmful Effect of its Native Form: An In Vitro Investigation of Cytotoxic Potential on Osteoblasts and Osteosarcoma Cells.
Dash P; Samal S; Prasad Panda G; Piras AM; Dash M
Macromol Biosci; 2023 Nov; 23(11):e2300211. PubMed ID: 37384621
[TBL] [Abstract][Full Text] [Related]
2. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
[TBL] [Abstract][Full Text] [Related]
3. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.
Lamoureux F; Baud'huin M; Ory B; Guiho R; Zoubeidi A; Gleave M; Heymann D; Rédini F
Oncotarget; 2014 Sep; 5(17):7805-19. PubMed ID: 25138053
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
[TBL] [Abstract][Full Text] [Related]
5. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.
Ory B; Moriceau G; Trichet V; Blanchard F; Berreur M; Rédini F; Rogers M; Heymann D
J Cell Mol Med; 2008 Jun; 12(3):928-41. PubMed ID: 18494934
[TBL] [Abstract][Full Text] [Related]
6. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.
Evdokiou A; Labrinidis A; Bouralexis S; Hay S; Findlay DM
Bone; 2003 Aug; 33(2):216-28. PubMed ID: 14499355
[TBL] [Abstract][Full Text] [Related]
7. Anticancer effects of zoledronic acid against human osteosarcoma cells.
Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
Labrinidis A; Hay S; Liapis V; Ponomarev V; Findlay DM; Evdokiou A
Clin Cancer Res; 2009 May; 15(10):3451-61. PubMed ID: 19401351
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid induces ferroptosis by upregulating POR in osteosarcoma.
Jiacong H; Qirui Y; Haonan L; Yichang S; Yan C; Keng C
Med Oncol; 2023 Apr; 40(5):141. PubMed ID: 37036615
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.
Moriceau G; Ory B; Mitrofan L; Riganti C; Blanchard F; Brion R; Charrier C; Battaglia S; Pilet P; Denis MG; Shultz LD; Mönkkönen J; Rédini F; Heymann D
Cancer Res; 2010 Dec; 70(24):10329-39. PubMed ID: 20971812
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells.
Açil Y; Arndt ML; Gülses A; Wieker H; Naujokat H; Ayna M; Wiltfang J
J Craniomaxillofac Surg; 2018 Apr; 46(4):538-546. PubMed ID: 29454604
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid modulates human osteosarcoma cells proliferation via GSK-3β activation.
Li S; Li JJ
Neoplasma; 2019 Sep; 66(5):766-775. PubMed ID: 31288526
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic Acid-containing Nanoparticles With Minimum Premature Release Show Enhanced Activity Against Extraskeletal Tumor.
Li X; Valdes SA; Alzhrani RF; Hufnagel S; Hursting SD; Cui Z
ACS Appl Mater Interfaces; 2019 Feb; 11(7):7311-7319. PubMed ID: 30689348
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
Schiraldi C; Zappavigna S; D' Agostino A; Porto S; Gaito O; Lusa S; Lamberti M; De Rosa M; De Rosa G; Caraglia M
Cancer Biol Ther; 2014; 15(11):1524-32. PubMed ID: 25482949
[TBL] [Abstract][Full Text] [Related]
16. A bifunctional zoledronate sustained-release system in scaffold: Tumor therapy and bone repair.
Di W; Shuai Y; Bo W; Wei T; Jinpeng H; Qian G; Deng Y
Colloids Surf B Biointerfaces; 2023 Feb; 222():113064. PubMed ID: 36481508
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells.
Liu M; Sun LL; Li YJ; Li HY; Zhang J; Li BH; Ye ZM
Int Immunopharmacol; 2015 Sep; 28(1):160-7. PubMed ID: 26071219
[TBL] [Abstract][Full Text] [Related]
18. Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.
Wolfe TD; Pillai SP; Hildreth BE; Lanigan LG; Martin CK; Werbeck JL; Rosol TJ
Clin Exp Metastasis; 2011 Apr; 28(4):377-89. PubMed ID: 21374084
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid - a multiplicity of anti-cancer action.
Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
[TBL] [Abstract][Full Text] [Related]
20. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
Ryu K; Murata H; Koto K; Horie N; Matsui T; Nishigaki Y; Sakabe T; Takeshita H; Itoi M; Kimura S; Ashihara E; Maekawa T; Fushiki S; Kubo T
Anticancer Res; 2010 Jul; 30(7):2713-20. PubMed ID: 20683003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
